Category Archives: Mesenchymal Stem Cells

Stem cell scientists have capitalised on the electrical properties of a widely used nanomaterial to develop cells which may allow the regeneration of cardiac cells. The breakthrough has been led by a team of scientists at the Regenerative Medicine Institute (REMEDI) at the National University of Ireland Galway in conjunction with Trinity College Dublin. Heart disease is the leading cause of death in Ireland. Once damaged by heart attack, cardiac muscle has very little capacity for self-repair and at present there are no clinical treatments available to repair damaged cardiac muscle tissue. Over the last 10 years, there has been tremendous interest in developing a cell-based therapy to address this problem. Since the use of a patient's own heart cells is not a viable clinical option, many researchers are working to try to find an alternative source of cells that could be used for cardiac tissue repair. REMEDI researchers Dr Valerie Barron and Dr Mary Murphy have brought together a multi-disciplinary team of Irish materials scientists, physicists and biologists from REMEDI at National University of Ireland Galway and Trinity College Dublin to address this problem. The researchers recognised that carbon nanotubes, a widely used nanoparticle, is reactive to electrical stimulation. … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2012 UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 2:30 p.m. ET in New York City. A live webcast of the presentation may be accessed through the Investors page of the Companys website at http://www.Osiris.com. A replay of the webcast will be available for one week following the conference. About Osiris Therapeutics Osiris Therapeutics, Inc., having developed the worlds first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix for burns and chronic wounds, and Ovation for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign patents. Osiris, Prochymal, Grafix … Continue reading →

ScienceDaily (Sep. 19, 2012) Stem cell scientists have capitalised on the electrical properties of a widely used nanomaterial to develop cells which may allow the regeneration of cardiac cells. The breakthrough has been led by a team of scientists at the Regenerative Medicine Institute (REMEDI) at the National University of Ireland Galway in conjunction with Trinity College Dublin. Heart disease is the leading cause of death in Ireland. Once damaged by heart attack, cardiac muscle has very little capacity for self-repair and at present there are no clinical treatments available to repair damaged cardiac muscle tissue. Over the last 10 years, there has been tremendous interest in developing a cell-based therapy to address this problem. Since the use of a patient's own heart cells is not a viable clinical option, many researchers are working to try to find an alternative source of cells that could be used for cardiac tissue repair. REMEDI researchers Dr Valerie Barron and Dr Mary Murphy have brought together a multi-disciplinary team of Irish materials scientists, physicists and biologists from REMEDI at National University of Ireland Galway and Trinity College Dublin to address this problem. The researchers recognised that carbon nanotubes, a widely used nanoparticle, is … Continue reading →

Queenstown Regenerative Medicine - http://www.queenstownRM.co.nz Professor Richard Boyd and Dr Dan Bates Latest developments of Stem Cell Therapy and Regenerative Medicine Queenstown Regenerative Medicine, in association with Monash University Immunology and Stem Cell Centre (MISCL), has the pleasure of requesting your attendance at an evening lecture by Prof Richard Boyd, Head of MISCL and Dr Dan Bates, Sports Medicine Physician from Melbourne AFL Club. Professor Richard Boyd is a world leader in the research and development of potential uses of stem cells to treat disease in both human and animal. He is the Director of Australia's largest and most prestigious Stem Cell Laboratory and a recipient of numerous International Awards for unique research into how stem cells and the immune system develop and how they have their effects in the body. Professor Boyd's talk will give an overall background to stem cells and the work going on around the world to put these cellular therapies and regenerative medicine into the clinic. Doctor Dan Bates is a Sports Medicine Physician working with Professor Boyd in the development and use of cellular medicine applications in the field of Sports Medicine and musculoskeletal injuries. Dan is the current team doctor of the Melbourne … Continue reading →

Public release date: 17-Sep-2012 [ | E-mail | Share ] Contact: Nicole White nicole.white@cshs.org 310-423-5215 Cedars-Sinai Medical Center LOS ANGELES Sept. 17, 2012 Leading scientists and clinicians from across the nation will discuss the latest findings on potential stem cell treatments for diabetes and eye diseases at the second Cedars-Sinai Regenerative Medicine Scientific Symposium. WHO: Stem cell scientists, clinicians and industry leaders. The symposium is being hosted by the Cedars-Sinai Regenerative Medicine Institute, led by Clive Svendsen, PhD. The institute brings together basic scientists with specialist clinicians, physician scientists and translational scientists across multiple medical specialties to convert fundamental stem cell studies to therapeutic regenerative medicine. FEATURED RESEARCH: The symposium's morning session will feature an overview of the current state of stem cells and diabetes, including efforts to start the first clinical trials with stem cells for the treatment of diabetes. Other research to be presented includes an update on regenerative medicine approaches to treating macular degeneration, a progressive deterioration of the eye that causes gradual loss of vision. This will include an update from Gad Heilweil , MD, on a key, stem-cell clinical trial on macular degeneration at the University of California Los Angeles. WHEN: Sept. 21, 2012 8:30 … Continue reading →

Miami, FL (PRWEB) September 17, 2012 GeneCell International, a trusted provider in the processing and preservation of umbilical cord blood, today announced it would present this new industry changing tissue engineering technology to a panel of more than 100 leading dentists. The technology will allow for the collection and storage of Dental Pulp Stem Cells, a type of multi-potent adult stem cell found in the pulp chamber of teeth, which show a strong potential to treat a variety of diseases. GeneCells Director of Research and Laboratory Operations, Dr. Todd R. Flower, is set to speak on Saturday, September 22, from 1:00 to 4:00 p.m. at the Cherokee Ranch & Castle. GeneCell is the only Stem Cell Processing and Cryogenic Storage Laboratory to offer this cutting-edge, regenerative medicine, technology at its state-of-the-art facility headquartered in Miami, FL. In addition to Dr. Flowers talk, Charis Ober, founder of Save the Cord Foundation, with more than 25 years of experience in the pharmaceutical and biotech industries, will be speaking about the benefits of cord blood banking. Umbilical cord blood, a clinically proven stem cell source that is currently used to treat approximately 80 different diseases was one of the first stem cells sources … Continue reading →

PARAMUS, N.J.--(BUSINESS WIRE)-- Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). The Company also announced that Chief Executive Officer Michael Cohen made a presentation at the National Investment Banking Associations (NIBA) 123rd Investment Conference yesterday at the New York Marriott Downtown in New York City. The single-center Phase 1 clinical trial, Mobilization of Stem Cells with UMK 121 in Patients with Cirrhosis, will enroll 15 patients with ESLD. The trial will study the safety of mobilization of stem cells in this patient population, as well as the effects of mobilization of stems cells from bone marrow to the peripheral circulation on liver function. Baburao Koneru, M.D., Professor and Chief of the Division of Transplant and Hepatobiliary Surgery at New Jersey Medical School, will serve as the trials principal investigator. We are extremely pleased to announce that our trial will be conducted at this highly respected institution … Continue reading →

Embryonic stem cells have been dubbed "the sleeper issue" of the 2012 election, but stem-cell research (taking cells from human embryos to create new cells that can treat disease) has long been a hot-button topic. The problem is that embryos traditionally are destroyed to extract the cells--something that plenty of people are uncomfortable with. But if there was a way to extract human embyronic stem cells without destroying anything, well, that shouldnt create any ethical quandaries. Advanced Cell Technology, a biotechnology company specializing in cellular therapies, thinks it has the solution. ACT uses an embryonic stem-cell-removal technique that doesnt destroy anything: It removes a single cell from embryos that are in the eight-cell stage--in other words, extremely early on. Its identical to whats done in in-vitro fertilization clinic for genetic testing of diseases like Tay-Sachs and Huntingtons Disease. "Its a non-destructive, non-harmful method of extracting these cells and creating embryonic stem cells. There are thousands of babies born every year having this exact kind of genetic testing done," says ACT CEO Gary Rabin. The cells propagate infinitely, so once you have what you need, you never have to go back to an in-vitro fertilization clinic to get more. ACT hasnt … Continue reading →

Orgenesis Inc. (ORGS) is an emerging biotechnology firm developing a new technology for regeneration of functional insulin-producing cells, thus enabling normal glucose regulated insulin secretion, via cell therapy. In this interview, Jacob BenArie MBA, B.Sc., President & CEO shares some detailed thoughts about his firm: Question: Several cutting-edge treatments for diabetes have been proposed over the years. Why is now the right time to develop your approach, involving the use of a patient`s own cells to secrete insulin? Jacob BenArie: Orgenesis`s approach involves transdifferentiation, which is the conversion of one adult cell type into an alternate type of adult cell with a distinct function. This approach bypasses the hazard of tumor formation upon implantation associated with two alternative approaches, involving the use of embryonic stem cells or induced pluripotent stem cells. Transdifferentiation is currently being analyzed for feasibility and safety in preclinical studies. Given the conceptual breakthrough represented by this process, it is not entirely surprising that it is not yet used in the clinic. By the year 2000, only a little more than a decade ago, common knowledge held that adult tissues in mammals are terminally differentiated. It takes comprehensive studies to change this dogma and demonstrate the clinical … Continue reading →

PARAMUS, N.J.--(BUSINESS WIRE)-- Proteonomix, Inc. (PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-sponsored Phase 1 clinical trial with its patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). Numoda is leading provider of clinical trial information and logistics services to life sciences companies. Initiating this clinical trial represents a major milestone for Proteonomix and we are delighted to report additional progress toward this goal, said Proteonomix Chief Technology Officer Steven Byle. UMK-121 combines two existing FDA-approved drugs with the intention of mobilizing mesenchymal stem cells from bone marrow to the peripheral circulation. This proprietary drug combination is designed to reduce inflammation and increase angiogenesis to restore liver function, potentially extending the life of ESLD patients awaiting liver transplant. We hope to begin this trial in the upcoming months. Earlier this month, Proteonomix signed a master agreement with Numoda for clinical trial services. In August, the U.S. Food and Drug Administration granted Proteonomix permission to conduct a Phase 1 clinical trial with UMK-121 in patients with ESLD. About Proteonomix, Inc. Proteonomix is … Continue reading →